Buy out value will be after completion of the first phase trial for at least one of the two lead drugs, or possibly both, and will be based on market potential minus the cost of completion for market approval minus the estimated time and cost remaining to market.
IMO, effective psoriasis treatment = $3 billion to $7 billion and effective Kevetrin = similar value
Total $6 - $14 billion. I get a lot of money left over after subtracting time, cost, and likelihood for failure/approval.
Any buy out price will be disconnected from market pps, unless it runs to double-digit numbers first.